Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B.
Nabi H, et al. Among authors: christensen lb.
RMD Open. 2022 Nov;8(2):e002560. doi: 10.1136/rmdopen-2022-002560.
RMD Open. 2022.
PMID: 36418087
Free PMC article.